1. Introduction {#s0005}
===============

Essential tremor (ET) is the most common movement disorder in adults ([@bb0140], [@bb0155]) with significant impact on patients\' abilities to perform daily activities ([@bb0050]). Abnormal activity of central tremor network is considered as a cause ([@bb0045], [@bb0195]) although the precise pathogenesis remains incompletely understood ([@bb0075], [@bb0150]). Transcranial high intensity Magnetic Resonance-guided Focused UltraSound (MRgFUS) targeting the ventral intermediate nucleus of the thalamus (Vim) is a significant development in the field of functional neurosurgery that offers an incisionless approach to treat ET. It creates thermal lesions through an intact skull with immediate results with the ability to assess the patient for both therapeutic benefit and side effects between sonications. The efficacy of MRgFUS for treating ET has been reported both in smaller institutional series ([@bb0080], [@bb0145]) as well as a larger randomized clinical trial ([@bb0085]).

The VIM nucleus is approximately 4 × 4 × 6 mm^3^ in size ([@bb0160]) and anatomically has been described as the cerebellar receiving area of the thalamus before the fibers project to the motor cortices ([@bb0090], [@bb0100], [@bb0105]), although it is incompletely defined from a connectivity standpoint and cerebellothalamic fibers are likely not absolutely unique to the ViM nucleus. Indirect targeting is the most common method to define the location of Vim. Atlas-derived coordinates are superimposed onto a patient\'s unique magnetic resonance imaging (MRI) scan and stereotactic coordinates are defined in relation to a point on the anterior commissure -- posterior commissure (AC-PC) line ([@bb0005], [@bb0040], [@bb0070]). The precise targeting of VIM is crucial for successful surgical intervention and is associated with improved surgical outcomes ([@bb0180]). The limitations of indirect targeting using atlas-based coordinates have long been recognized due to the limited data set on which atlases are created and extensive interpatient anatomical and functional variability ([@bb0170], [@bb0165], [@bb0175]).

Diffusion tensor imaging (DTI) is a non-invasive technique that has been used to delineate the internal anatomy of the thalamus by tracing white matter tracts to cortical areas and cerebellum that are involved in tremor ([@bb0055], [@bb0100], [@bb0120], [@bb0125], [@bb0130], [@bb0190], [@bb0200]). Probabilistic tractography takes into account intra-voxel crossing fibers ([@bb0030]), estimates the pathways that originate at any given seed voxel and provides quantitative information about the probability of structural connectivity that a white matter tract will pass through any other voxel in the brain ([@bb0025]). Individualized DTI segmentation tractography may provide more robust anatomic data for targeting thalamic nuclei and it has the potential to guide and refine thalamic targeting for improved efficacy in thalamotomies and reduced number of adverse events. In this study, we used retrospective imaging data from ET patients that underwent MRgFUS from the initial pilot trial reported by [@bb0080]. We hypothesize that the efficacious target area is localized within the part of the thalamus with the highest probability of connectivity with precentral gyrus, which contains premotor and primary motor cortices, since it plays an important role in tremor generation ([@bb0190]). Our goal is to understand the predictive value of probabilistic tractography guided thalamic targeting by defining how tractography-defined targets, lesion size, location and clinical outcomes interrelate.

2. Methods {#s0010}
==========

2.1. Patients {#s0015}
-------------

Twelve patients with refractory essential who were treated with MRgFUS targeting Vim in a pilot study at the University of Virginia ([@bb0080]) were evaluated in this analysis, for whom preoperative DTI sequences were available. All patients provided written informed consent. Details of MRgFUS procedure (including sonication, maximum temperature, and other clinical variables) have been described previously ([@bb0080]). Briefly, an MRI--guided focused ultrasound system (ExAblate Neuro, InSightec) was used to deliver therapeutic sonication to each patient targeting Vim contralateral to the affected hand. The Vim location was specified pre-operatively as three quarters of the length of the anterior-posterior commissural line and 14 to 15 mm lateral to the midline or 11 mm lateral to third ventricle. For each patient, Vim localization was adjusted further intraoperatively based on the suppression of tremor that each patient presented.

2.2. Clinical assessment {#s0020}
------------------------

As described at ([@bb0080]), Clinical Rating Scale for Tremor (CRTS) ([@bb0220]) was used for the clinical evaluation pre-treatment and 1 week, 1 month, 3 months and 12 months after MRgFUS treatment. Different components of CRTS were used to evaluate the tremor severity, the ability to perform tasks and functional disability of the patients. In current study, we use the tremor severity component to assess each patient\'s condition at different time points in a range of 0 to 32, with higher scores indicating high tremor severity. As described below, given the overall favorable response across all subjects, we leveraged differences in outcomes even amongst those with favorable outcomes by dividing the group into 2, which we refer to as those with "superior" and "inferior outcomes." To be clear, "inferior outcomes is not meant to imply "non-responder" but was a method used to compare across 2 groups.

2.3. Image acquisition {#s0025}
----------------------

For current study, T1-and T2- weighted and diffusion-weighted MR data, acquired at University of Virginia before and 1 month after treatment, were used. A 3 Tesla MRI scanner with 8-channel head array coil (Tim Trio, Siemens Medical Solutions, Germany) was used. A 2D twice-refocused DW-SE-EPI sequence was used for DTI acquisition. Diffusion tensor imaging parameters were: field of view 230 × 230; b value = 1000 s/mm^2^; 20 directions; number of slices = 30; matrix size = 128 × 128; repetition time/echo time = 4100/93 ms. High resolution structural images were collected using 3D MP-Rage sequence with the following parameters: repetition time/echo time/inversion time = 1900/1.94/900 ms; a flip angle of 9°; number of slices = 240; matrix = 256 × 256.

2.4. Regions of interest {#s0030}
------------------------

FreeSurfer (version 5.3.0, <http://surfer.nmr.mgh.harvard.edu>/) was used for cortical surface reconstruction and volumetric segmentation to automatically generate thalamic as well as pre- and post-central gyrus regions of interest (ROIs) on pre-treatment T1-weighted images for each patient. The MRgFUs treatment-induced lesion area was delineated on 1 month post-operative T2-weighted image registered to pre-treatment T1-weighted image ([Fig. 1](#f0005){ref-type="fig"}a, b, c). Specifically, the lesion was localized and then the maximum intensity value of the area around the localization point was retrieved. Based on the imaging findings previously reported ([@bb0080], [@bb0235]), 1 month after MRgFUS treatment the lesion consisted of 3 concentric zones with different diameters. In order to localize the center of the lesion, we used as upper threshold the maximum intensity value and as lower the 60% of the maximum intensity of the selected area and then the lesion was drawn manually for each subject. To register the ROIs and lesion area to preoperative DTI space, linear and non-linear transformations (FLIRT-FNIRT) ([@bb0010], [@bb0110]) were performed to register pretreatment T1 and DTI to MNI152 template (using mutual information as cost function, 6 degrees of freedom for DTI to T1 registration and 12 for registration to MNI152) and the derived transformation matrices were used for the transformation.Fig. 1Localization of MRgFUs treatment-induced lesion area and calculation of intersection area between lesion and thalamic probabilistic maps.a) At T2-weighted image registered to pre-treatment T1-weighted image the MRgFUs treatment-induced lesion area was localized and (b) based on the maximum intensity value of the lesion area (upper threshold: maximum intensity value - lower a percentage of 60% of the maximum intensity value), (c) the lesion was delineated (blue color). d) Fiber tract projections from the thalamic region with maximal connectivity with to the target (precentral gyrus in this case) were derived. e) Connectivity-based thalamic segmentation map (red-yellow map) to pre-central gyrus were found (zoom out (f)). (g) Segmentation map was thresholded at 30% of the maximum intensity value (green map) to find the voxels with high probability of connectivity to target area. (h) The lesion area was overlapped with the thalamic segmentation map and the intersection was calculated (light blue) (i).Fig. 1

2.5. Tractography analysis {#s0035}
--------------------------

Probabilistic diffusion tractography was performed to define structural connectivity between the thalamus with pre- and post-central gyrus ROIs using the FMRIB\'s Diffusion toolbox. Eddy current correction was used to apply affine registrations to each volume in the diffusion dataset to register it with the initial reference B0 volume prior performing tractography. Skull stripping was performed using the brain extraction tool (BET) ([@bb0215]). A multi-fiber diffusion model in FDT ([@bb0025]) was fitted on the data. This model uses Bayesian techniques to estimate a probability distribution function (PDF) on the principal fiber direction at each voxel, accounting for the possibility of crossing fibers within each voxel. Two fibers modeled per voxel, a multiplicative factor (i.e., weight) of 1 for the prior on the additional modeled fibers, and 1000 iterations before sampling ([@bb0035]). Using these PDFs and PROBTRACKX, we could then determine the probability of connectivity between thalamus and the pre- and post-central gyrus targets. From each voxel in the thalamic seed, 5000 streamlines were generated; a 0.2 curvature threshold was chosen, a loop check termination was used and the target masks were used as waypoint, termination and classification masks. The resulted tomographic probabilistic maps identified the regions within thalamus with the highest probability of connectivity with pre- and post-central gyrus ROIs ([Fig. 1](#f0005){ref-type="fig"}e--f).

The same parameters were used using the lesion itself as a seed in order to investigate the structural connectivity of MRgFUs treatment-induced lesion area with the whole brain. Five thousand samples per voxel were again generated from each patient\'s lesion seed to whole brain using the cerebrospinal fluid as an exclusion mask. Each patient\'s whole brain tractography map was divided by the overall number of streamlines and then binarized at 0.05 threshold value.

Based on the clinical score 1 month and 1 year after MRgFUS 11 of the 12 patients and 10 of 12 patients demonstrated improvement greater that 50%, respectively. Given the overall response to therapy was satisfactory across the majority of subjects, we leveraged the differential degrees of response, even amongst "responders." We used the median value of clinical improvement (0.84) to divide patients in two groups: one including the subjects with superior clinical outcome (*n* = 6, clinical improvement greater or equal to 0.84) and one with inferior (n = 6, clinical improvement \< 0.84)). Notably, "inferior outcomes" is not meant to imply "non-responders." The same approach was followed using the improvement in clinical score 1 year after MRgFUS and a cutoff value of 0.82 was used to label patients. Subjects that presented superior clinical outcome 1 month after MRgFUS had the same label also after 1 year ([Table 1](#t0005){ref-type="table"}). The 'common population map' was found by summing up all the binarized maps and identifying those voxels in the whole brain that were shared by at least 80% of the subjects. Finally, the percentage of improvement in clinical score between baseline and 1 month and 1 year after MRgFUs was assigned to each subject\'s binary whole brain map. These clinically-weighted maps were then averaged to find the 'average clinical efficacy map' at the two timepoints for the 12 patients. Each voxel\'s value in the 'average clinical efficacy map' corresponds to the average clinical outcome of the subjects that present connectivity to that specific voxel.Table 1Characterization of patients using clinical improvement score 1 month and 1 year after MRgFUS.Table 1PatientsClinical score1 m clinical improvement1 y clinical improvementTreated hand1 m1yCutoff: 0.84Cutoff: 0.82**fus001**20330.850.85**fus002**22680.730.64**fus004**29660.790.79**fus005**20001.001.00**fus006**16021.000.88**fus008**158110.470.27**fus009**24450.830.79**fus0010**19310.840.95**fus0011**2810170.640.39**fus0012**218100.620.52**fus0013**14021.000.86**fus0015**18021.000.89[^1]

2.6. Predictive value of the intersection between MRgFUS treatment-induced lesion and thalamic probabilistic maps {#s0040}
-----------------------------------------------------------------------------------------------------------------

For each subject, the maximum intensity value within each thalamic probability map (based on connectivity to pre- and post-central gyri) was determined. As the optimal threshold is unknown and we aimed to understand how best to apply probabilistic tractography to define thalamic targets, thresholds for each map were applied at 30% ([Fig. 1](#f0005){ref-type="fig"}g), 40% and 50% of this maximum value in order to identify the voxels within the thalamic probabilistic maps with the higher probability of connectivity to pre- and post-central gyri. The percentage overlap between the MRgFUs treatment-induced lesion and each probabilistic map at each threshold (and also without threshold) was derived. Also, the volume of MRgFUS lesion ([Fig. 1](#f0005){ref-type="fig"}c) and segmentation maps ([Fig. 1](#f0005){ref-type="fig"}f, g) were compared to the overlapping volume ([Fig. 1](#f0005){ref-type="fig"}h). As an initial assessment, we evaluated whether lesion volume relates to response. We then investigated the predictive value of probabilistic tractography guided thalamic targeting by defining how tractography-defined targets, lesion size and location, and clinical outcomes interrelate. We used empirical receiver operating characteristic (ROC) curves to examine the sensitivity and specificity at all possible cutoffs ([@bb0185]) of the overlapping.

3. Results {#s0045}
==========

3.1. MRgFUS treatment-induced lesion structural connectivity {#s0050}
------------------------------------------------------------

We evaluated whole brain probabilistic tractography seeded from the MRgFUS lesion ([Fig. 2](#f0010){ref-type="fig"}). The main differences between those with superior vs inferior clinical outcomes were located in connectivity to the pre- and post- central gyri as well as the brainstem/cerebellum ([Fig. 2](#f0010){ref-type="fig"}, green illustrates differences between groups). Superior clinical outcome was related to more dominant structural connectivity to both pre- and post- central gyrus and to the brainstem/cerebellum areas while inferior outcome was characterized by weak caudal projections to the cerebellum and precentral gyrus.Fig. 2Whole brain probabilistic tractography of shared fiber tract of MRgFUS induced lesion area.Tractography from the MRgFUS lesion demonstrates that patients with (a) superior clinical outcome (*n* = 6) (red common whole brain binary map) present stronger structural connectivity than patients with (b) inferior clinical outcome (*n* = 6) (blue common whole brain binary map) in pre- and post-central gyri and brainstem/cerebellum areas. The differences (c) between the common whole brain binary map of the two groups were localized in pre- and post-central gyri (green binary map) and to the caudal projection to the cerebellum (green binary map).Fig. 2

Likewise, the clinical efficacy map demonstrates that patients with higher clinical improvement 1 month and 1 year after MRgFUS present stronger structural connectivity to the pre- and post-central gyri and to the caudal projection to the cerebellum. ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Average clinical efficacy map using clinical improvement scores 1 month and 1 year after MRgFUS.The percentage of improvement in clinical score between baseline and 1 month and 1 year after MRgFUs was assigned to each subject\'s binary whole brain map. The resulted clinically-weighted maps were then averaged to find the 'average clinical efficacy map' at two time points. Each voxel\'s value in the 'average clinical efficacy map' corresponds to the average clinical outcome of the subjects that present connectivity to that specific voxel. In both time points the patients with higher clinical improvement present stronger connectivity to pre- and post-central gyri and brainstem/cerebellum areas (Red-Yellow map).Fig. 3

3.2. Overlapping volume between MRgFUS treatment-induced lesion and thalamic segmentation maps {#s0055}
----------------------------------------------------------------------------------------------

The overlap between the connectivity-based thalamic segmentation maps to each cortical region (red-yellow maps on [Fig. 1](#f0005){ref-type="fig"}) and lesion area (blue mask on [Fig. 1](#f0005){ref-type="fig"}) was evaluated. The average lesion volume was found 111 ± 26 mm^3^ and further investigation of the overlapping volume included only the area within thalamic segmentation probabilistic maps that characterized by higher probability of connectivity to target areas (green maps on [Fig. 1](#f0005){ref-type="fig"}) at different thresholds. Given the small size of data, we report all the raw data on [Table 2](#t0010){ref-type="table"}.Table 2Overlapping volume between MRgFUS treatment-induced lesion and thalamic segmentation maps.Table 2a) Thalamic segmentation map to precentral gyrusLesionTSMVOL_O(mm^**3**^)(VOL_O/VOL_L)%(VOL_O/VOL_TSM)%VVOL(mm^3^)VMINT30%40%50%NT30%40%50%NT40%50%NT30%40%50%**fus001**43010328,587406068166935855051036859521006657501.519.8110.0910.30**fus002**2927024,929391459441361973589212111630301690.351.541.131.02**fus004**66712128,46643815170313187102108452715893722122.0914.3814.4414.71**fus005**56510340,91145807430757609493101888273988580711.3611.6213.4614.81**fus006**68612537,426390367971274109592777655741625246331.135.105.214.42**fus008**52812629,77037587098102584868812612612512310010099981.7812.2914.7417.88**fus009**3779032,7494503780813951234109536363636404040400.462.582.923.29**fus0010**69412637,7834101686275060847980574838634538301.177.607.897.93**fus0011**45010729,4724225702778467156098383022923628211.394.854.473.93**fus0012**2716532,34038937710103387874763636261979795940.826.107.068.17**fus0013**74113533,76845806133800692604124676257925046422.028.388.969.44**fus0015**65315636,97043448814867562364132 855737855437241.509.8010.1410.16  b) Thalamic segmentation map to postcentral gyrusLesionTSMVOL_O(mm^3^)(VOL_O/VOL_L)%(VOL_O/VOL_TSM)%VVOL(mm^3^)VMINT30%40%50%NT30%40%50%NT30%40%50%NT30%40%50%**fus001**43010329,117465369428217155941034944371004843361.485.976.156.23**fus002**2927025,16842366001113394773721212018303029260.351.852.112.44**fus004**66712128,75949775223845723640108676156895550462.077.938.448.75**fus005**56510343,10447527828979845732101848074988278721.298.589.4710.11**fus006**68612537,460407368031273109194177757065626056521.135.896.426.91**fus008**52812629,454444270228417286281267971621006356491.799.399.759.87**fus009**3779032,90549147845110779853636000400000.460.000.000.00**fus0010**69412638,5994496701081162147180413225633325201.145.065.155.31**fus0011**45010729,8154207710851343937198200922001.380.390.000.00**fus0012**2716534,176479981481157103994663393634976055520.773.373.463.59**fus0013**74113536,4104630661311291014918124524542923933311.884.614.444.58**fus0015**65315637,02044578826181615461196132126119102858176651.506.947.708.53[^2]

For each patient, the voxels and the volume (VOL) of the MRgFUS induced lesion and of each thalamic segmentation map to pre-central (a) and post-central gyrus (b) were found. Also for each thalamic map the maximum intensity value was retrieved and then different percentages of the maximum intensity value (30%, 40% and 50%) were applied to threshold the thalamic segmentation maps. The volume of the thresholded maps was calculated and the overlapping (VOL_O) between the connectivity-based thalamic segmentation maps to both targets (pre-central and post-central gyrus) and lesion area was evaluated. Finally, we compared the overlapping volume (thresholded/unthresholded maps) with the MRgFUS induced lesion ((VOL_O/VOL_L) %) and the thalamic segmentation maps ((VOL_O/VOL_TSM) %).Fig. 4Prediction of superior clinical outcome using the volume of overlapping between thalamic segmentation maps and MRgFUS induced lesion.The volume of intersection between the MRgFUs treatment-induced lesion area and thalamic-segmentation maps to both targets precentral (a) and postcentral (b) gyrus ((unthresholded (i)/thresholded maps (ii--iv))) was used as feature to predict the superior clinical outcome. The area under the ROC curve was 0.80 (a-ii, red color) (95% confidence interval:0.54--1; *p* \< 0.005) using as feature the overlapping of thalamic probabilistic map to motor target (at 30% threshold) and (b-ii, red color) 76% (95% confidence interval:0.48--1; *p* \< 0.005) when as feature it was used the thalamic probabilistic map to sensory target (at 30% threshold).Fig. 4

3.3. Prediction of improved clinical outcome {#s0060}
--------------------------------------------

The initial assessment between the volume of the lesion and the percentage of clinical improvement 1 month and 1 year after MRgFUS, did not demonstrate significant results between the two parameters (Supplementary material [Fig. 1](#f0025){ref-type="graphic"}). The analysis of ROC curves showed that the volume of overlap between the lesion and the thalamic probabilistic maps can predict which patients had a superior clinical outcome after MRgFUS treatment. The area under the ROC curve was 0.80 (95% confidence interval:0.54--1; *p* \< 0.005) when considering the overlap of the MRgFUS lesion with the thalamic probabilistic map to precentral gyrus using a 30% threshold and 0.76 (95% confidence interval: 0.48--1; *p* \< 0.005) when considering the overlap with the thalamic probabilistic map to postcentral gyrus (at 30% threshold) ([Fig. 4](#f0020){ref-type="fig"}). Using other thresholds (or no threshold) for the probabilistic thalamic maps resulted in lower areas under the ROC curve ([Fig. 4](#f0020){ref-type="fig"}). When volume of intersection was normalized by the volume of lesion or thalamic segmentation map, low accuracy values were identified. Likewise, the value of the mean Euclidean distance between the lesions\' voxels with the voxel with the maximum intensity value within thalamic segmentation map was low (Supplementary material [Fig. 2](#f0030){ref-type="fig"}, [Fig. 3](#f0035){ref-type="fig"}).

4. Discussion {#s0065}
=============

Given inherent variability in brain anatomy across patients, we sought to evaluate a probabilistic tractography approach to predict outcomes and potentially target MRgFUS thalamotomy. In particular, we employ methods that are automated, are widely available, and do not require manual segmentation or user input to define seeds or masks, ensuring the method is practical and potentially adoptable. As hypothesized, we found that the percentage overlap between connectivity-based thalamic segmentation maps to the pre- and post-central gyri and the thalamic lesion predicted the improvement in clinical outcome. Patients with higher percentage of overlap between the lesion and the tractography-defined thalamic targets demonstrated superior response to MRgFUS treatment compared to other patients.

Consistent with previous literature mostly from DBS studies ([@bb0065], [@bb0060], [@bb0055], [@bb0095], [@bb0100], [@bb0125], [@bb0130], [@bb0190], [@bb0200], [@bb0205]), we report that better clinical outcome was associated with stronger structural connectivity to pre- and post-central gyri (including premotor cortex), brainstem and cerebellum compared to the connectivity of patients with inferior clinical outcomes ([Fig. 2](#f0010){ref-type="fig"}). The fewer tracts observed in the group with inferior outcomes is likely due to less consistency amongst this group relative to the consistency of tracts in those with superior outcomes. Tractography results from lesion demonstrated the caudal projection to the cerebellum as a characteristic tract that confirms the role of Vim as the anatomically cerebellar receiving area of the thalamus. These results contribute to a better understanding of the underlying pathology and highlight the predictive power of lesion overlap with tractography-defined targets. Probabilistic tractography may therefore be an effective non-invasive imaging tool that can be used to overcome current imaging limitations, particularly when internal anatomy is not clearly evident on structural imaging ([@bb0170], [@bb0165], [@bb0175]). While these results are intriguing, one must still consider that the observed differences in whole brain tractography may be due to technical issues and may not necessarily be treatment, outcome, or group-related.

In previous studies, probabilistic and deterministic approaches were used for thalamic targeting in ET patients ([@bb0190], [@bb0115], [@bb0100], [@bb0125], [@bb0210]). [@bb0190] reported a new method of targeting patient-specific therapeutic thalamic target for the treatment of tremor based on individualized probabilistic tractography analysis of thalamic connectivity patterns to premotor and supplementary motor cortices. The same approach ([@bb0115]) was validated for the definition of Vim in a tremor-dominant Parkinson\'s disease patient. Others have used probabilistic tractography to explore the individual thalamic nuclei connectivity profiles and to reveal the inter-individual variability of the anatomical position of nuclei areas ([@bb0100], [@bb0125]). In a number of recent studies ([@bb0200], [@bb0095], [@bb0205]), deterministic tractography has been used for targeting the thalamus for treatment of tremor. Interestingly, one approach is to use tractography to indirectly target the ViM, by delineating the pyramidal tract and medial lemniscus, and targeting 3 mm medial and anterior to these, respectively ([@bb0200]). In contrast to this empiric approach, our current results suggest that having the lesion overlap with thalamic regions with connectivity with the postcentral gyrus may play a therapeutic role. More direct targeting of the cerebello-thalamo-premotor cortical fiber tract have also been reported to identify the optimal target ([@bb0095], [@bb0205]). Still, the AUC is not 100% for any of the comparisons, suggesting this is not a perfect methodology and highlighting that targeting and patient outcomes are multifactorial and cannot completely be accounted for by connectivity-based target estimation.

Still, there is a controversy in literature about which diffusion tractography analytic approach is more reliable for reproducing known anatomy, with results highly dependent on data quality, the algorithm selected, and the parameter settings ([@bb0135], [@bb0225]). Deterministic tractography is a fast approach, but is characterized by increased uncertainty in dense areas where it cannot resolve crossing fibers and is prone to sampling limitations ([@bb0015]). The probabilistic approach on the other hand is computationally demanding and time intensive compared to deterministic and it can be more sensitive to non-dominant fiber pathways and more prone to false positives ([@bb0035]). However, its data-driven nature may provide a better practical approach in delineation of individualized anatomy over deterministic. Moreover, computational limitations are increasingly overcome with accelerated hardware platforms. Ultimately, a head-to-head comparison of deterministic vs probabilistic tractography algorithms will need to be done for each target and each application, but this is beyond the focus of the current work. Tractography constitutes the only non-invasive available tool for the evaluation of white-matter microstructure and to address the clinical need for white matter pathways characterization ([@bb0020]). Moreover, even if it is not reliable at precisely reproducing known anatomy, these methods can still theoretically provide usable biomarkers to guide functional neurosurgery.

The main limitation of the current study is the small sample size of our population. MRgFUS thalamotomy for ET was an investigational approach and the available data were restricted. However, with the recent FDA approval, the clinical research will be rapidly expanded. We believe even if the available data are restricted, we have to optimize opportunities and make investigations that will contribute to the better understanding of the field. Further studies are needed with larger sample size population to assess improvements in treatment efficacy using tractography for preoperative Vim targeting and to explore the predictive value of probabilistic tractography guided thalamic targeting for ET patients. Also, the number of directions (20 directions) that was used in the current DTI acquisition protocol may be another limitation of the study since it can introduce uncertainty on the results. Larger number of directions lead to improved precision in the tracking results and a reduction in the spread of the results ([@bb0230]).

5. Conclusion {#s0070}
=============

Transcranial MRgFUS is a significant new development in functional neurosurgery field. Imaging analysis techniques like probabilistic tractography may potentially be used to increase the efficacy and consistency of outcomes with MRgFUS and potentially shorten treatment times by identifying optimal targets in advance of treatment. These methods may be applicable to other incisionless approaches for treatment of tremor, such as stereotactic radiosurgery. The current results provide further validation of this potentially useful methodology. Prospective evaluation, comparison with deterministic tractography, and development of appropriate clinical platforms are necessary prior to consideration of routine adoption in clinical practice.

The following are the supplementary data related to this article.Fig. 1Correlation of Lesion size with clinical outcome.The correlation between the size of the lesion and the percentage of improvement in clinical outcome 1 month and 1 year after MRgFUS was examined. Results showed that there is not a significant correlation between the two parameters.Fig. 1Fig. 2Prediction of superior clinical outcome using the volume of overlapping between the MRgFUS induced lesion and thalamic segmentation maps normalized by the Volume of Lesion (VOL_o/VOL_Lesion) and normalized by the Volume of thalamic segmentation map (VOL_O/VOL_Segmentation Map).The volume of overlapping between the MRgFUS induced lesion and thalamic segmentation maps to both targets precentral (a) and postcentral (b) gyrus ((unthresholded (i)/thresholded maps (ii-iv))) was normalized by the volume of Lesion (VOL_o/VOL_Lesion) and the volume of thalamic segmentation map (VOL_O/VOL_Segmentation Map) and then were used as features to predict the superior clinical outcome.Low accuracy results were found in both cases.Fig. 2Fig. 3Prediction using the mean Euclidean distance between lesion area and thalamic segmentation maps.The euclidean distance (a) between the voxel with the maximum intensity value at the lesion area on PostT2_to PreT1 image and the voxel with the maximum intensity value of thalamic segmentation map was calculated. Also, the mean euclidean distance (b) between all voxels of lesion with the voxel with the maximum intensity value of thalamic segmentation maps was found. The resulted measures were used to predict the superior clinical improvement after MRgFUS. ROC analysis revealed low accuracy values for both cases.Fig. 3
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[^1]: The median value 0.84 of the improvement in clinical score 1 month (m) after MRgFUS was used as cutoff value to divide patients in two groups: one including the subjects with superior clinical outcome (*n* = 6) and one with inferior (*n* = 6). The same approach was followed using the improvement in clinical score 1 year (y) after MRgFUS and the median value of 0.82 was used as cutoff to label patients. Subjects that characterized with superior clinical outcome 1 month after MRgFUS presented superior outcome also after 1 year.

[^2]: V = voxels, VOL = volume, VOL_O = volume of overlapping, MI = maximum intensity, NT = no threshold, TSM = thalamic segmentation map, VOL_L = volume of MRgFUS induced lesion, VOL_TSM = volume of thalamic segmentation.
